There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on United Therapeutics (UTHR) and Anthem (ANTM) with bullish sentiments.
United Therapeutics (UTHR)
In a report released yesterday, Martin Auster from Credit Suisse maintained a Buy rating on United Therapeutics, with a price target of $129.00. The company’s shares closed last Thursday at $111.31, close to its 52-week high of $116.99.
According to TipRanks.com, Auster is a 4-star analyst with an average return of 11.7% and a 53.4% success rate. Auster covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, BioMarin Pharmaceutical, and Allena Pharmaceuticals.
United Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $141.50, a 30.8% upside from current levels. In a report issued on April 20, Oppenheimer also maintained a Buy rating on the stock with a $155.00 price target.
See today’s analyst top recommended stocks >>
Anthem (ANTM)
Credit Suisse analyst A.J. Rice maintained a Buy rating on Anthem today and set a price target of $355.00. The company’s shares closed last Thursday at $277.18.
According to TipRanks.com, Rice is a 4-star analyst with an average return of 5.0% and a 56.7% success rate. Rice covers the Healthcare sector, focusing on stocks such as Genesis Healthcare, Acadia Healthcare, and Community Health.
Anthem has an analyst consensus of Strong Buy, with a price target consensus of $330.90, a 18.7% upside from current levels. In a report released today, Morgan Stanley also maintained a Buy rating on the stock with a $423.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
